1177469-53-2

Basic information

• Product Name: 4-(5-naphthalen-1-yl-3-trifluoromethyl-pyrazol-1-yl)-phenylamine
• CAS NO: 1177469-53-2
• Molecular Weight: 353.346
• Mol File: 1177469-53-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(5-naphthalen-1-yl-3-trifluoromethyl-pyrazol-1-yl)-phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-naphthalen-1-yl-3-trifluoromethyl-pyrazol-1-yl)-phenylamine(1177469-53-2)
• EPA Substance Registry System: 4-(5-naphthalen-1-yl-3-trifluoromethyl-pyrazol-1-yl)-phenylamine(1177469-53-2)

Safety Data

• Hazardous Substances Data: 1177469-53-2(Hazardous Substances Data)

Upstream product

• 1252678-95-7 5-Naphthalen-1-yl-1-(4-nitro-phenyl)-3-trifluoromethyl-1H-pyrazole 
• 7639-68-1 4,4,4-trifluoro-1-(1-naphthyl)-1,3-butanedione 
• 100-16-3 4-nitrophenylhydrazone 
• 941-98-0 1'-naphthacetophenone 

Relevant articles and documents

Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA.

Pyrazole derivatives as anti-francisella agents

A series of celecoxib derivatives defined by Formula I: were prepared and evaluated for their ability to inhibit the gram-negative bacteria Francisella tularensis. Pharmaceutical compositions including celecoxib derivatives and their use in methods for treating or preventing infection by Francisella tularensis in a subject are described.